Ginkgo Bioworks

(NYSE) DNA

Current Price$7.88

Market Cap$492.99M

Since IPO (2021)-98%

5 Year-98%

1 Year-19%

1 Month-7%

Ginkgo Bioworks last closing stock price
Metric	Price	Date
Last close	USD 7.91	2026-07-17

Ginkgo Bioworks stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-12.98%	USD 9.09	2026-07-10
1 month	-7.49%	USD 8.55	2026-06-17
3 month	-1.49%	USD 8.03	2026-04-17
Year to date	-4.81%	USD 8.31	2025-12-31
1 year	-18.95%	USD 9.76	2025-07-17
3 year	-91.59%	USD 94.00	2023-07-18
5 year	-98%	USD 396.40	2021-07-16
Since inception	-98.05%	USD 404.80	2021-04-19

Ginkgo Bioworks Financials at a Glance

Market Cap

$492.99M

Revenue (TTM)

$141.31M

Net Income (TTM)

-$304.39M

EPS (TTM)

-$5.39

P/E Ratio

-1.47

Dividend

$0.00

Beta (Volatility)

2.54 (High)

Dividend

$0.00

Beta (Volatility)

2.54 (High)

Price

$7.88

Volume

37,792

Open

$8.15

Price

$7.88

Volume

37,792

Open

$8.15

Previous Close

$7.88

Daily Range

$7.70 - $8.15

52-Week Range

$5.37 - $17.58

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

2.54 (High)

Price

$7.88

Volume

37,792

Open

$8.15

Previous Close

$7.88

Daily Range

$7.70 - $8.15

52-Week Range

$5.37 - $17.58

Estimated Earnings Date

Aug 6, 2026

DNA News

Person in a lab looking through a microscope

Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today

Eric VolkmanSep 17, 2024

Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?

David Jagielski, CPASep 5, 2024

Chemist team looking beaker of green chemical

Page 1

DNA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ginkgo Bioworks

Ginkgo helps companies use biology to make new products. It treats DNA like computer code to design better medicines. The company also tracks and stops biological threats.

How Ginkgo Programs Life

Cell Engineering Solutions: Custom research and development services where scientists design and optimize biological organisms like yeast or bacteria for industrial use.
Cell Engineering Tools: Automated hardware and data services, such as the Reconfigurable Automation Cart (RAC) system, for clients to run their own experiments.
Canopy Biosecurity: Monitoring programs that collect and test samples at airports and borders to find harmful germs like viruses.
Horizon Platform: A digital tool that uses data and artificial intelligence to track and analyze biological risks around the world.

Strategic Growth and Partnerships

Expanded service offerings in 2024 to include biological research tools and data generation services for external customers.
Commenced restructuring actions in 2024 to reduce operational spending and manage organizational changes.
Partnered with Google Cloud to develop artificial intelligence models for biological engineering and data analysis.
Collaborated with Bayer Crop Sciences to develop biological solutions for nitrogen fixation in crops to reduce fertilizer use.
Integrated technology from Zymergen to enhance laboratory automation and hardware design for biological research.

Why Is the Platform Different?

Ginkgo uses a flexible, automated laboratory system built with reconfigurable carts to generate large amounts of biological data for its partners. This platform creates a reusable library of genetic information that helps scientists design and test new cell programs more efficiently.

Checking the Financial Vitals

Revenue was $33.4 million in Q4 2025, down 23.8% from $43.8 million in Q4 2024.
Gross profit reached $41.5 million in Q4 2025, up 21.4% from $34.2 million in the previous year.
Net loss reached $80.8 million in Q4 2025, an improvement from the $107.5 million loss reported in Q4 2024.
Free cash flow was negative $63 million in Q4 2025, a 12.2% decline from negative $56.1 million in Q4 2024.

The Long View

Ginkgo has moved from offering custom biological research to providing a broad platform of automation tools and biosecurity monitoring. This shift reflects a strategy to lower research barriers while building global infrastructure for biological intelligence.

AI Generated • May 5, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

485

CEO

Jason Kelly, PhD

Website

www.ginkgo.bio

Headquarters

Boston, MA 02210, US

DNA Financials

Key Financial Metrics (TTM)

Gross Margin

74.97%

Operating Margin

-210.66%

Net Income Margin

-215.41%

Return on Equity

-57.31%

Return on Capital

-33.24%

Return on Assets

-29.46%

Earnings Yield

-68.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$492.99M

Shares Outstanding

62.32M

Volume

37.79K

Avg. Volume

1.24M

Financials (TTM)

Gross Profit

$105.94M

Operating Income

-$297.68M

EBITDA

-$210.87M

Operating Cash Flow

-$165.97M

Capital Expenditure

-$17.30M

Free Cash Flow

-$183.27M

Cash & ST Invst.

$373.46M

Total Debt

$410.70M

Ginkgo Bioworks Performance Analysis

Ginkgo Bioworks annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 477,706,000	52.2%
2023	2023-12-31	USD 251,455,000	-47.4%
2024	2024-12-31	USD 227,043,000	-9.7%
2025	2025-12-31	USD 170,155,000	-25.1%

Ginkgo Bioworks sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	2.7%
Q3	2025-09-30	-21.7%
Q4	2025-12-31	-14.0%
Q1	2026-03-31	-41.7%

Ginkgo Bioworks annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -50.15	7.0%
2023	2023-12-31	USD -18.37	-63.4%
2024	2024-12-31	USD -10.54	-42.6%
2025	2025-12-31	USD -5.64	-46.5%

Ginkgo Bioworks sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	34.5%
Q3	2025-09-30	-31.8%
Q4	2025-12-31	1.4%
Q1	2026-03-31	2.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$19.47M

-59.7%

Gross Profit

$3.58M

-90.1%

Gross Margin

18.37%

N/A

Market Cap

$492.99M

N/A

Market Cap/Employee

$1.02M

N/A

Employees

485

N/A

Net Income

-$82.59M

+9.2%

EBITDA

-$63.34M

+7.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$373.46M

-27.8%

Total Debt

$410.70M

-5.5%

Accounts Receivable

$19.82M

-27.1%

Inventory

$0.00

N/A

Long Term Debt

$410.70M

-5.5%

Short Term Debt

$0.00

N/A

Return on Assets

-29.46%

N/A

Return on Invested Capital

-31.22%

N/A

Free Cash Flow

-$48.37M

+18.2%

Operating Cash Flow

-$46.43M

+9.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VALNValneva SE

VALNValneva SE$5.00-1.57%

ARVNArvinas, Inc.

ARVNArvinas, Inc.$8.01-0.25%

REPLReplimune Group, Inc.

REPLReplimune Group, Inc.$10.23+7.46%

MGTXMeiraGTx Holdings plc

MGTXMeiraGTx Holdings plc$12.44+0.89%

AVBPArriVent BioPharma, Inc.

AVBPArriVent BioPharma, Inc.$33.19+1.31%

VIRVir Biotechnology, Inc.

VIRVir Biotechnology, Inc.$9.43+0.32%

IOVAIovance Biotherapeutics, Inc.

IOVAIovance Biotherapeutics, Inc.$5.00+7.30%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$6.53-0.02%

NOKNokia

NOKNokia$10.12-0.03%

PATHUiPath

PATHUiPath$12.15+0.01%

JOBYJoby Aviation

JOBYJoby Aviation$7.23-0.01%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$123.99-0.05%

TAT&T

TAT&T$21.81-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.53-0.05%

Questions About DNA

What is the current price of Ginkgo Bioworks?

Ginkgo Bioworks is trading at $7.88 per share.

What is the 52-week range for Ginkgo Bioworks?

Over the past 52 weeks, Ginkgo Bioworks has traded between $5.37 and $17.58.

How much debt does Ginkgo Bioworks have?

As of the most recent reporting period, Ginkgo Bioworks reported total debt of $410.70M.

How much cash does Ginkgo Bioworks have on hand?

Ginkgo Bioworks reported $150.75M in cash and cash equivalents in its most recent financial results.

What is Ginkgo Bioworks’s dividend yield?

Ginkgo Bioworks does not currently have a dividend yield.

Ginkgo Bioworks

Ginkgo Bioworks Financials at a Glance

DNA News

Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today

Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?

2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock

This 1 AI Stock Could Revolutionize Biotech and Pharma

Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?

Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?

Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?

Why Ginkgo Bioworks Stock Is Sinking Today

DNA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ginkgo Bioworks

How Ginkgo Programs Life

Strategic Growth and Partnerships

Why Is the Platform Different?

Checking the Financial Vitals

The Long View

DNA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ginkgo Bioworks Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About DNA

What is the current price of Ginkgo Bioworks?

What is the 52-week range for Ginkgo Bioworks?

How much debt does Ginkgo Bioworks have?

How much cash does Ginkgo Bioworks have on hand?

What is Ginkgo Bioworks’s dividend yield?

Premium Investing Services